ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
Organon and Co

Organon and Co (OGN)

15.56
-0.41
(-2.57%)
마감 02 2월 6:00AM
15.74
0.18
(1.16%)
시간외 거래: 9:48AM

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.500.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-
7.500.000.000.000.000.000.00 %00-
10.005.506.600.006.050.000.00 %00-
12.502.953.203.303.075-0.30-8.33 %205101/02/2025
15.000.901.000.970.95-0.28-22.40 %273,40301/02/2025
17.500.000.000.000.000.000.00 %00-
20.000.060.050.060.0550.000.00 %08-
22.500.000.000.000.000.000.00 %00-

개인 투자자를 위한 전문가급 도구.

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.500.000.000.000.000.000.00 %00-
5.000.002.150.000.000.000.00 %00-
7.500.000.750.000.000.000.00 %00-
10.000.020.750.020.3850.000.00 %07-
12.500.050.050.050.050.000.00 %0142-
15.000.300.350.340.3250.0936.00 %3361,59801/02/2025
17.500.000.000.000.000.000.00 %00-
20.004.105.304.104.70-0.90-18.00 %10531/01/2025
22.500.000.000.000.000.000.00 %00-

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
731.1M
REBNReborn Coffee Inc
US$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
US$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
US$ 1.54
(56.50%)
13.87M
CYCNCyclerion Therapeutics Inc
US$ 3.92
(54.33%)
82.57M
ENVBEnveric Biosciences Inc
US$ 2.0899
(-46.41%)
1.57M
NIVFNewGenIvf Group Ltd
US$ 0.1489
(-42.51%)
14.8M
GLSTGlobal Star Acquisition Inc
US$ 8.83
(-39.10%)
23.89k
PRPHProPhase Labs Inc
US$ 0.2633
(-38.02%)
872.46k
SPGCSacks Parente Golf Inc
US$ 0.5601
(-37.86%)
7.27M
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
NVDANVIDIA Corporation
US$ 120.07
(-3.67%)
388.54M
RIMEAlgorhythm Holdings Inc
US$ 0.02565
(5.12%)
338.75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0355
(-11.25%)
236.29M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1938
(30.77%)
234.8M

OGN Discussion

게시물 보기
Monksdream Monksdream 1 년 전
OGN not so hot from a chart standpoint
👍️0
LordDarley LordDarley 4 년 전
Looks good.
There is also a very nice analysis on seeking Alpha. Shows pros and cons, and is professional quality IMHO. Much more detail than the Barron's article.
👍️0
DewDiligence DewDiligence 4 년 전
Barron’s bullish on OGN:

https://www.barrons.com/articles/jobs-report-fed-interest-rates-inflation-51622846230 Organon (OGN), which Merck (MRK) jettisoned this past week, could be another winner. This is a classic spinoff situation. Organon is a group of noncore Merck businesses—off-patent drugs sold mainly overseas, biosimilars, and a women’s health business—that may fare better as an independent company.
“You easily can see how this business could have been lost inside of Merck and been undermanaged relative to the rest of the portfolio,” says James Hounsell, a senior research analyst at Smead Capital Management, a Merck shareholder. “That’s when the magic happens with spinoffs.”

The shares trade around $34, giving the company a market value of $8.6 billion, plus about $9 billion of net debt. Merck shareholders received one Organon share for every 10 of Merck. Organon trades for just six times 2020 profits of $5.90 a share. Similar earnings are expected this year.

Organon isn’t as cheap when valued against projected 2021 earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.3 billion, based on its enterprise value of equity value plus net debt. Then, it trades around eight times, in line with mature drug companies.

At a May investor day, Merck projected $6.1 billion to $6.4 billion of 2021 revenue for Organon and annual sales increases in the low- to mid-single digits. The dividend hasn’t been set yet, but based on Organon’s financial guidance, it could be about 3%.

Major drivers for the company are expected to be an implantable women’s contraceptive called Nexplanon and biosimilars, which are generic versions of bioengineered drugs.

“This is a stable, predictable business with low- to mid-single digit growth organically,” Organon CEO Kevin Ali tells Barron’s. He is bullish on the growth outlook for the women’s health business, now about 25% of revenue, plus the opportunity for potential acquisitions.

Given its low price/earnings ratio, Organon has good appreciation potential if it can deliver on its financial goals.
👍️0
DewDiligence DewDiligence 4 년 전
OGN spin-off from MRK begins trading today:

https://www.businesswire.com/news/home/20210602006079/en
👍️0

최근 히스토리

Delayed Upgrade Clock